---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 11-DOC | 11-deoxycorticosterone |
| AA | Aldosterone antagonist |
| ABPM | Ambulatory blood pressure monitoring |
| ACC | American College of Cardiology |
| ACC.25 | American College of Cardiology's Annual Scientific Session & Expo 2025 |
| ACE | Angiotensin-converting enzyme |
| ACEi | Angiotensin-converting enzyme inhibitor |
| ACTH | Adrenocorticotropic hormone |
| ADEs | Adverse drug events |
| AE, AEs | Adverse event |
| AESIs | Adverse events of special interest |
| AF | Atrial fibrillation |
| AHA | American Heart Association |
| AHFS | American Hospital Formulary Service |
| AHI | Apnea-hypopnea index |
| aHR | Adjusted hazard ratio |
| AHT, AHTs | Antihypertensive; antihypertensive treatments |
| AKI | Acute kidney injury |
| ANCA | Anti-neutrophil cytoplasmic antibody |
| ANP | Atrial natriuretic peptide |
| AOBP | Automated office blood pressure |
| AODBP | Automated office diastolic blood pressure |
| aOR | Adjusted odds ratio |
| AOSBP | Automated office systolic blood pressure |
| ARB, ARBs | Angiotensin II receptor blocker |
| aRHT | Apparent resistant hypertension |
| ARIC | Atherosclerosis Risk in Communities study |
| ARR | Aldosterone-renin ratio |
| ASBP | Ambulatory systolic blood pressure |
| ASCVD | Atherosclerotic cardiovascular disease |
| ASI, ASIs | Aldosterone synthase inhibitor |
| aTRH | Apparent treatment-resistant hypertension |
| AUC, AUCs | Area under the concentration-time curve |
| AUC0–∞ | Area under the concentration-time curve from time 0 to infinity |
| AUC0–24 | Area under the concentration-time curve from 0 to 24 hours |
| AVS | Adrenal vein sampling |
| BAX | Baxdrostat |
| BB, BBs | Beta-blocker |
| BEBO | Stichting Beoordeling Ethiek Biomedisch Onderzoek (Foundation for the Review of Ethics in Biomedical Research, Assen, Netherlands) |
| BI 690517 | Boehringer Ingelheim development code for vicadrostat |
| BID | Twice daily |
| BiPAP | Bilevel positive airway pressure |
| BMI | Body mass index |
| BNP | Brain natriuretic peptide |
| BP, BPs | Blood pressure |
| BPC-E | Blood Pressure Control for Patients With Hypertension (HEDIS measure) |
| BPLTTC | Blood Pressure Lowering Treatment Trialists' Collaboration |
| C-LIFE | Lifestyle modification program (dietary counseling, behavioral weight management, and exercise) in the TRIUMPH trial |
| C5Research | Cleveland Clinic Coordinating Center for Clinical Research |
| CAD | Coronary artery disease |
| CARDIA | Coronary Artery Risk Development in Young Adults study |
| CAS | Chemical Abstracts Service |
| CaTRH | Controlled apparent treatment-resistant hypertension |
| CBP | Controlling High Blood Pressure (HEDIS measure) |
| CCB, CCBs | Calcium channel blocker |
| CDC | Centers for Disease Control and Prevention |
| CED | Coverage with Evidence Development |
| CEPAC | Comparative Effectiveness Public Advisory Council |
| CEST | Central European Summer Time |
| CHD | Coronary heart disease |
| CHF | Congestive heart failure |
| CHMP | Committee for Medicinal Products for Human Use (European Medicines Agency) |
| CI, CIs | Confidence interval |
| CKD | Chronic kidney disease |
| CKD-EPI | Chronic Kidney Disease Epidemiology Collaboration |
| CL | Confidence limit |
| CLAD | Censored least absolute deviations |
| CLICK | Chlorthalidone in Chronic Kidney Disease trial |
| CLR | Renal clearance |
| Cmax | Maximum observed plasma concentration |
| CMS | Centers for Medicare & Medicaid Services |
| COR | Class of recommendation |
| CPAP | Continuous positive airway pressure |
| CPT | Current Procedural Terminology |
| cRH | Controlled resistant hypertension |
| CrI | Credible interval |
| CRMN | Cost-related medication nonadherence |
| CRN | Cost-related nonadherence |
| CRO | Contract research organization |
| CT | Central Time; computed tomography |
| CUAs | Cost-utility analyses |
| CV | Cardiovascular |
| CVA | Cerebrovascular accident |
| CVD | Cardiovascular disease |
| CVOT | Cardiovascular outcomes trial |
| CYP | Cytochrome P450 |
| CYP11B1, hCYP11B1 | 11β-hydroxylase (cytochrome P450 11B1); human CYP11B1 |
| CYP11B2, hCYP11B2 | Aldosterone synthase (cytochrome P450 11B2); human CYP11B2 |
| CYP3A, CYP3A4 | Cytochrome P450 3A, cytochrome P450 3A4 |
| DASH | Dietary Approaches to Stop Hypertension |
| DB | Double-blind |
| DBP | Diastolic blood pressure |
| DMC | Data Monitoring Committee |
| DRC | Direct renin concentration |
| DRG | Diagnosis-related group |
| ECG, ECGs | Electrocardiogram |
| ED | Emergency department |
| eGFR, eGFRs | Estimated glomerular filtration rate |
| EMR | Electronic medical record |
| ENaC | Epithelial sodium channel |
| EoS | End of study |
| EoT | End of treatment |
| EPL | Eplerenone |
| EQ-5D | EuroQol 5-Dimension questionnaire |
| EQ-5D-5L | EuroQol 5-Dimension 5-Level questionnaire |
| ERA, ERAs | Endothelin receptor antagonist |
| ESC | European Society of Cardiology |
| ESH | European Society of Hypertension |
| ESKD | End-stage kidney disease |
| ESRD | End-stage renal disease |
| ESS | Epworth Sleepiness Scale |
| ET, ET-1 | Endothelin, endothelin-1 |
| ETA, ETB | Endothelin receptor type A, endothelin receptor type B |
| EtD | Evidence to Decision |
| EU | European Union |
| EudraCT | European Union Drug Regulating Authorities Clinical Trials Database |
| evLY, evLYs | Equal value life year |
| FDA | U.S. Food and Drug Administration |
| FEC, FECs | Free-equivalent combination |
| FOSQ, FOSQ-10 | Functional Outcomes of Sleep Questionnaire; Functional Outcomes of Sleep Questionnaire-10 |
| GDMT | Guideline-directed medical therapy |
| GDP | Gross domestic product; guideline development panel |
| GFR | Glomerular filtration rate |
| GLP-1 | Glucagon-like peptide-1 |
| GPER | G protein-coupled estrogen receptor |
| GPR30 | G protein-coupled receptor 30 |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| HbA1c, HbA1C | Glycosylated hemoglobin |
| HBP | High blood pressure |
| HBPB | Health Benefit Price Benchmark |
| HBPM | Home blood pressure monitoring |
| HCL | Hydrochloride |
| HCTZ | Hydrochlorothiazide |
| HEDIS | Healthcare Effectiveness Data and Information Set |
| hERG | Human ether-a-go-go-related gene (cardiac potassium channel) |
| HF | Heart failure |
| HR, HRs | Hazard ratio; heart rate |
| HrQoL, HRQoL | Health-related quality of life |
| HT | Hypertension |
| HTA | Health technology assessment |
| HTN | Hypertension |
| IC | Intercurrent events |
| IC50 | Half-maximal inhibitory concentration |
| ICD-9 | International Classification of Diseases, Ninth Revision |
| ICE | Intercurrent event |
| ICER, ICERs | Institute for Clinical and Economic Review; incremental cost-effectiveness ratio |
| ICF | Informed consent form |
| ICH | Intracerebral hemorrhage |
| ID | Identification |
| IHD | Ischemic heart disease |
| IHE | Ischemic heart event |
| INN | International Nonproprietary Name |
| IQR | Interquartile range |
| ISPOR | ISPOR, The Professional Society for Health Economics and Outcomes Research |
| LOR | Lorundrostat |
| LP | Lorundrostat-placebo (treatment sequence) |
| LS | Least squares |
| LSM, LSmeans | Least squares mean |
| LY, LYs | Life year |
| MA | Medicare Advantage |
| MACE | Major adverse cardiovascular events |
| MAD, MADs | Multiple ascending dose |
| MAR | Missing at random |
| MATE, MATE1 | Multidrug and toxin extrusion; multidrug and toxin extrusion 1 |
| MCS | Mental component summary |
| MD | Mean difference |
| MDT | Multidisciplinary team |
| MEPS | Medical Expenditure Panel Survey |
| MI | Myocardial infarction |
| MLS-101 | Mineralys Therapeutics development code for lorundrostat |
| MNAR | Missing not at random |
| MR | Mineralocorticoid receptor |
| MRA, MRAs | Mineralocorticoid receptor antagonist |
| MT-4129 | Mitsubishi Tanabe Pharma development code for lorundrostat |
| NA | Not applicable |
| NADAC | National Average Drug Acquisition Cost |
| NDA | New Drug Application |
| NDC | National Drug Code |
| NEJM | The New England Journal of Medicine |
| NHANES | National Health and Nutrition Examination Survey |
| NMA | Network meta-analysis |
| non-RH | Nonresistant hypertension |
| NPLB | No Patient Left Behind |
| NS | Not significant |
| NSAIDs | Nonsteroidal anti-inflammatory drugs |
| NT-proBNP | N-terminal pro-B-type natriuretic peptide |
| OLE | Open-label extension |
| OR | Odds ratio |
| OSA | Obstructive sleep apnea |
| P/I | Promising but Inconclusive (ICER evidence rating) |
| PA | Primary aldosteronism |
| PAC | Plasma aldosterone concentration |
| PAP | Positive airway pressure |
| PATHWAY-2 | Prevention And Treatment of Hypertension With Algorithm-based therapY 2 trial |
| PBO | Placebo |
| PCS | Physical component summary |
| PD | Pharmacodynamics |
| PDUFA | Prescription Drug User Fee Act |
| PI | Principal investigator |
| PIE | Pre-approval information exchange |
| PK | Pharmacokinetics |
| PL | Placebo-lorundrostat (treatment sequence) |
| po | Orally |
| PR | PR interval (electrocardiogram) |
| PRA | Plasma renin activity; Pharmaceutical Research Associates |
| PROMIS | Patient-Reported Outcomes Measurement Information System |
| PROMIS-SD | Patient-Reported Outcomes Measurement Information System - Sleep Disturbance |
| PSP | Patient support program |
| QALY, QALYs | Quality-adjusted life year |
| QD | Once daily |
| QRS | QRS complex (electrocardiogram) |
| QT | QT interval (electrocardiogram) |
| QTc | Heart-rate corrected QT interval |
| QTcF | QT interval corrected for heart rate by Fridericia's method |
| RAAS | Renin-angiotensin-aldosterone system |
| RALES | Randomized Aldactone Evaluation Study |
| RAS | Renin-angiotensin system |
| RCT, RCTs | Randomized controlled trial |
| RDN | Renal denervation |
| REGARDS | Reasons for Geographic and Racial Differences in Stroke study |
| ReHOT | Resistant Hypertension Optimal Treatment trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| RF | Radiofrequency |
| rfRDN | Radiofrequency renal denervation |
| RH | Resistant hypertension |
| RHT | Resistant hypertension |
| rHTN, RHTN | Resistant hypertension |
| RR | Risk ratio; relative risk |
| RTSM | Randomization and trial supply management |
| RTW | Randomized treatment withdrawal |
| SAD, SADs | Single ascending dose |
| SAEs | Serious adverse events |
| SAP | Statistical analysis plan |
| SB | Single-blind |
| SBP | Systolic blood pressure |
| SD | Standard deviation |
| SE | Standard error |
| seated-SBP | Seated office systolic blood pressure |
| SEC | U.S. Securities and Exchange Commission |
| SEM | Standard error of the mean |
| SEPA | Standardized education and physician advice |
| SF-12, SF-36 | 12-item and 36-item Short Form Health Surveys |
| SF-6D | Short Form 6-Dimension utility index |
| SGLT2 | Sodium-glucose cotransporter 2 |
| SGLT2i | Sodium-glucose cotransporter 2 inhibitor |
| siRNA | Small interfering ribonucleic acid |
| SiSBP | Sitting systolic blood pressure |
| SMBP | Self-measured blood pressure |
| sNDA | Supplemental New Drug Application |
| SoC | Standard of care |
| SPC, SPCs | Single-pill combination |
| SPIR | Spironolactone |
| SRI | Sleep-Related Impairment (PROMIS) |
| t1/2 | Apparent terminal elimination half-life |
| T2DM | Type 2 diabetes mellitus |
| TBC | Team-based care |
| TDM | Therapeutic drug monitoring |
| TEAE, TEAEs | Treatment-emergent adverse event |
| Tmax | Time to maximum observed plasma concentration |
| TRH | Treatment-resistant hypertension |
| trHTN | Treatment-resistant hypertension |
| TRIUMPH | Treating Resistant Hypertension Using Lifestyle Modification to Promote Health trial |
| UACR | Urinary albumin-to-creatinine ratio |
| UAldo | Urinary aldosterone |
| uAOBP | Unattended automated office blood pressure |
| UaTRH | Uncontrolled apparent treatment-resistant hypertension |
| ucHTN | Uncontrolled hypertension |
| UCort | Urinary cortisol |
| uHTN | Uncontrolled hypertension |
| UK | United Kingdom; urinary potassium |
| UNa | Urinary sodium |
| uRDN | Ultrasound renal denervation |
| uRH | Uncontrolled resistant hypertension |
| US | United States |
| USA | United States of America |
| USPSTF | U.S. Preventive Services Task Force |
| WAC | Wholesale acquisition cost |
| WHO | World Health Organization |
| WTP | Willingness to pay |
| ΔQTcF | Change from baseline in QTcF |
| ΔΔQTcF | Placebo-corrected change from baseline in QTcF |

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
